Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 19 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-2.10 Insider Own10.70% Shs Outstand11.38M Perf Week-32.55%
Market Cap3.33M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float10.17M Perf Month56.58%
Income-11.06M PEG- EPS next Q- Inst Own2.46% Short Float5.62% Perf Quarter-6.06%
Sales1.63M P/S2.04 EPS this Y- Inst Trans0.71% Short Ratio0.04 Perf Half Y-41.50%
Book/sh-0.54 P/B- EPS next Y- ROA-131.95% Short Interest0.57M Perf Year-71.57%
Cash/sh0.05 P/C6.17 EPS next 5Y- ROE-1656.23% 52W Range0.14 - 1.26 Perf YTD-46.76%
Dividend Est.- P/FCF- EPS past 5Y71.09% ROI- 52W High-76.76% Beta-0.80
Dividend TTM- Quick Ratio0.22 Sales past 5Y-50.00% Gross Margin37.25% 52W Low102.07% ATR (14)0.07
Dividend Ex-Date- Current Ratio0.22 EPS Y/Y TTM51.98% Oper. Margin-615.57% RSI (14)53.86 Volatility18.57% 24.52%
Employees4 Debt/Eq- Sales Y/Y TTM-72.28% Profit Margin-679.86% Recom1.00 Target Price5.00
Option/ShortNo / No LT Debt/Eq- EPS Q/Q54.60% Payout- Rel Volume0.08 Prev Close0.31
Sales Surprise-100.00% EPS Surprise21.74% Sales Q/Q-100.00% Earnings- Avg Volume12.76M Price0.29
SMA2023.10% SMA5017.35% SMA200-39.56% Trades Volume1,081,721 Change-6.90%
Jul-15-24 08:19AM
Jul-12-24 11:56AM
07:39AM Loading…
Jul-09-24 07:39AM
Jul-08-24 10:08AM
Jul-02-24 09:52PM
Jul-01-24 08:00AM
Jun-21-24 07:52AM
Jun-20-24 07:28AM
Jun-03-24 10:53AM
May-30-24 04:00PM
07:00AM Loading…
Apr-16-24 07:00AM
Apr-10-24 08:00AM
Apr-09-24 08:00AM
Nov-14-23 04:30PM
Nov-07-23 08:30AM
Oct-23-23 08:30AM
Sep-27-23 08:30AM
Aug-30-23 07:09AM
Aug-17-23 08:30AM
Aug-15-23 08:30AM
Aug-01-23 08:30AM
Jul-24-23 08:15AM
Jun-14-23 10:30AM
Jun-05-23 08:15AM
May-16-23 08:00AM
07:20AM Loading…
May-12-23 07:20AM
May-02-23 04:30PM
Apr-21-23 05:46PM
Apr-18-23 08:45AM
Mar-21-23 08:35AM
Mar-15-23 09:05AM
Mar-09-23 08:30AM
Mar-08-23 08:05AM
Feb-01-23 09:05AM
Jan-24-23 09:00AM
Jan-23-23 09:02AM
Jan-10-23 09:00AM
Jan-05-23 09:00AM
Dec-12-22 08:30AM
Dec-07-22 09:10AM
Dec-01-22 07:11AM
Nov-22-22 09:00AM
Nov-17-22 06:12AM
Nov-15-22 07:30AM
Oct-19-22 09:00AM
Oct-18-22 09:00AM
Oct-06-22 08:00AM
Sep-14-22 05:02PM
Aug-25-22 06:45AM
Aug-18-22 09:15AM
Aug-16-22 07:30AM
Aug-01-22 08:30AM
Jul-06-22 09:00AM
Jun-14-22 09:00AM
Jun-07-22 09:04AM
Jun-06-22 06:10AM
Jun-02-22 09:00AM
May-26-22 09:15AM
May-20-22 09:15AM
May-13-22 06:00AM
May-10-22 09:17AM
May-03-22 02:24PM
Apr-29-22 09:15AM
Apr-18-22 06:25AM
Apr-12-22 10:15AM
Apr-05-22 09:15AM
Apr-01-22 08:00AM
Mar-30-22 09:15AM
Mar-22-22 09:15AM
Mar-15-22 09:15AM
Feb-22-22 09:15AM
Feb-15-22 09:15AM
Feb-01-22 09:15AM
Jan-18-22 09:15AM
Dec-14-21 09:18AM
Dec-01-21 03:25PM
Nov-29-21 03:50PM
Nov-22-21 10:23AM
Nov-15-21 09:00AM
Oct-19-21 09:00AM
Sep-15-21 07:30AM
Sep-08-21 07:30AM
Aug-31-21 06:22AM
Aug-23-21 09:58AM
Aug-17-21 10:01AM
Jul-14-21 07:30AM
Jul-07-21 10:37AM
Jun-08-21 07:30AM
Jun-02-21 07:30AM
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Carlsbad, CA.